Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Posted by Geri Gentry on May 12th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $573.10, for a total value of $5,444,450.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $23,218,000.30. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Price Performance

NASDAQ UTHR traded up $11.86 on Tuesday, hitting $581.74. The company had a trading volume of 397,406 shares, compared to its average volume of 485,338. The company has a market capitalization of $24.69 billion, a PE ratio of 21.47, a PEG ratio of 1.80 and a beta of 0.60. The company’s fifty day moving average price is $552.09 and its 200-day moving average price is $503.34. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the prior year, the business posted $6.63 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 27.4 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Check Out Our Latest Stock Analysis on UTHR

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC lifted its position in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC raised its stake in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the last quarter. Finally, Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics in the 3rd quarter worth approximately $317,617,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.